1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Esclerosis Múltiple

Esclerosis Múltiple

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Monreal E, Fernández-Velasco JI, Sainz de la Maza S, Espiño M, Villarrubia N, Roldán-Santiago E, Aladro Y, Cuello JP, Ayuso-Peralta L, Rodero-Romero A, Chico-García JL, Rodríguez-Jorge F, Quiroga-Varela A, Rodríguez-Martín E, Pilo de la Fuente B, Martín-Ávila G, Martínez-Ginés ML, García-Domínguez JM, Rubio L, Llufriu S, Comabella M, Montalban X, Álvarez-Bravo G, Veiga-González JL, Masjuan J, Costa-Frossard L, Villar LM.

    Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 26(14): .

    [doi:10.3390/ijms26146898]

  • Cayuela L, García-Muñoz C, Sainz de la Maza S, Cayuela A.

    Prevalence of multiple sclerosis in Spain. Estimates from the Primary Care Clinical Database (BDCAP).

    Neurologia . 40(5): 447-455.

    [doi:10.1016/j.nrleng.2025.04.010]

  • Dema M, Eixarch H, Hervera A, Castillo M, Villar LM, Montalban X, Espejo C.

    Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis: Role of Immunosenescence.

    Aging Cell . 24(5): .

    [doi:10.1111/acel.14491]

  • Oreja-Guevara C, Meca-Lallana JE, Gómez-Estévez I, Ara JR, Pérez MÁH, Gil JG, Torres AMA, de la Fuente BP, Ramió-Torrentà L, Madueño SE, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Valcárcel MA, Ginés MLM, Montero YEB, Real AML, González-Quintanilla V, de Silanes CL, Martínez-Rodríguez JE, Costa-Frossard L, Redondo MG, Fontcuberta AL, Castellanos-Pinedo F, Merino JAG, Fernández CM, Castillo-Triviño T, Meca-Lallana V, Martínez JP, Rodríguez-Antigüedad A, González JMP, Morales EA, Molina IP, Sánchez DMS, Varo NH, Vázquez MA, Barrios JMR, Río J.

    Economic burden of secondary progressive multiple sclerosis: DISCOVER study.

    BMC HEALTH SERVICES RESEARCH . 25(1): 525-525.

    [doi:10.1186/s12913-025-12592-1]

  • Piñar-Morales R, Calle-Calle R, Carrasco-Garcia M, Davila-Arias C, Villar-Guimerans LM, Barrero Hernandez FJ.

    Case Report: Neurofilament light chain in the follow up of progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with ocrelizumab.

    FRONTIERS IN PHARMACOLOGY . 16: 1571699-1571699.

    [doi:10.3389/fphar.2025.1571699]

  • Dominguez-Mozo MI, López-Mecández D, Villar LM, Costa-Frossard L, Villarrubia N, Aladro Y, Pilo B, Montalbán X, Comabella M, Casanova-Peño I, González-Suárez I, Martínez-Ginés ML, García-Domínguez JM, García-Calvo E, Machuca-Marcos A, Luque-Garcia JL, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R.

    Short-chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profile.

    Annals of Clinical and Translational Neurology . 12(3): 478-490.

    [doi:10.1002/acn3.52259]

  • Comabella M, Pappolla A, Monreal E, Fissolo N, Sao-Avilés AC, Arrambide G, Carbonell-Mirabent P, Gutierrez L, Cobo-Calvo Á, Tur C, Villacieros-Álvarez J, Vidal-Jordana Á, Castilló J, Galán I, Espiño M, Ariño H, Bollo L, Rodríguez Barranco M, Midaglia LS, Carvajal R, Villarrubia N, Fernández Velasco JI, Rodríguez Acevedo B, Costa Frossard LF, Vilaseca A, Auger C, Zabalza A, Sainz de la Maza S, Mongay-Ochoa N, Río J, Sastre-Garriga J, Rovira À, Tintoré M, Villar LM, Montalban X.

    Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis.

    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION . 12(2): .

    [doi:10.1212/NXI.0000000000200370]

  • García-Domínguez JM, Maurino J, Meca-Lallana JE, Landete L, Meca-Lallana V, García-Arcelay E, Agüera-Morales E, Caminero AB, Martínez-Yélamos S, Querol L, Medrano N, Gómez-Ballesteros R, Villar LM, Monreal E, Saposnik G.

    Attitudes of Neurologists Toward Serum Neurofilament Light-Chain Testing in the Management of Relapsing-Remitting Multiple Sclerosis with Cognitive Impairment.

    Journal of Personalized Medicine . 15(2): .

    [doi:10.3390/jpm15020069]

  • Martínez García B, Chico García JL, Pérez Gil D, Garay Albízuri P, Llanes Ferrer A, García Alcántara G, Cabañas Engenios G, Matute Lozano MC, de Felipe Mimbrera A, Vera Lechuga R, Cruz Culebras A, Carrión Sánchez I, Fernández-Golfín C, Masjuan J, García Madrona S.

    Grading Right-to-Left Shunt With Transforaminal Doppler: A Valid Approach in Patients With Cryptogenic Stroke.

    J NEUROIMAGING . 35(1): .

    [doi:10.1111/jon.70023]

  • Comabella M, Hegen H, Villar LM, Rejdak K, Sao-Avilés A, Behrens M, Sastre-Garriga J, Mongay N, Berek K, Martínez-Yelamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke J, Carbonell-Mirabent P, Valls-Carbó A, Rosenstein I, Alvarez-Lafuente R, Castillo-Triviño T, Otaegui D, Llufriu S, Blanco Y, Sánchez-López AJ, García-Merino A, Fissolo N, Gutiérrez L, Villacieros-Álvarez J, Monreal E, Wiendl H, Montalban X, Lünemann JD.

    Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.

    JOURNAL OF NEUROLOGY . 272(1): 26-26.

    [doi:10.1007/s00415-024-12763-w]

  • Sainz-Amo R, Rodero-Romero A, Monreal E, Chico-García JL, Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Veiga-González JL, de la Maza SS, Masjuan J, Costa-Frossard L, Villar LM.

    Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(23): .

    [doi:10.3390/ijms252313153]

  • Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R, Sainz de la Maza S, García-Sánchez MI, Llufriu S, Casanova B, Comabella M, Martínez-Yélamos S, Galimberti D, Ramió-Torrentà L, Martínez-Ginés ML, Aladro Y, Ayuso L, Martínez-Rodríguez JE, Brieva L, Villarrubia N, Eichau S, Zamora J, Rodero-Romero A, Espiño M, Blanco Y, Saiz A, Montalbán X, Tintoré M, Domínguez-Mozo MI, Cuello JP, Romero-Pinel L, Ghezzi L, Pilo de la Fuente B, Pérez-Miralles F, Quiroga-Varela A, Rubio L, Rodríguez-Jorge F, Chico-García JL, Sainz-Amo R, Masjuan J, Costa-Frossard L, Villar LM.

    Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

    Brain . 147(12): 4084-4093. Nº de citas: 2

    [doi:10.1093/brain/awae260]

  • Meca-Lallana JE, Robles R, Landete L, Téllez N, García-Domínguez JM, Garcés P, Costa-Frossard L.

    A Clinical Care Algorithm for Detecting Progression in Multiple Sclerosis: RetratEMos Project.

    Cureus . 16(11): 74001-74001.

    [doi:10.7759/cureus.74001]

  • Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM.

    Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

    Frontiers in immunology . 15: 1480676-1480676.

    [doi:10.3389/fimmu.2024.1480676]

  • Aguirre C, Alonso-Torres A, Agüera E, García-Domínguez JM, Montero-Escribano P, González-Quintanilla V, Costa-Frossard L, Oreja-Guevara C, Reyes-Garrido V, Caminero-Rodríguez AB, Riancho J, Sánchez O, Forero L, Pérez-Parra F, Ares-Luque A, Téllez N, Arzalluz-Luque J, Iglesias F, Casado-Ruiz V, Castellano-Vicente AJ, Borrega L, Galán V, de Antonio LAR, Romero C, García-Rodríguez R, Cano-Orgaz AT, Sánchez-Menoyo JL, Pérez-Ruiz D, Gutiérrez-Martin F, Hernández-Echevarría L, Meca-Lallana V.

    Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.

    CLINICAL DRUG INVESTIGATION . 44(11): 829-838.

    [doi:10.1007/s40261-024-01397-5]

  • Oreja-Guevara C, Martínez-Yélamos S, Eichau S, Llaneza MÁ, Martín-Martínez J, Peña-Martínez J, Meca-Lallana V, Alonso-Torres AM, Moral-Torres E, Río J, Calles C, Ares-Luque A, Ramió-Torrentà L, Marzo-Sola ME, Prieto JM, Martínez-Ginés ML, Arroyo R, Otano-Martínez MÁ, Brieva-Ruiz L, Gómez-Gutiérrez M, Rodríguez-Antigüedad A, Galán Sánchez-Seco V, Costa-Frossard L, Hernández-Pérez MÁ, Landete-Pascual L, González-Platas M, Meca-Lallana JE.

    Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.

    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS . 17: .

    [doi:10.1177/17562864241284372]

  • Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J.

    Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 90: 105787-105787.

    [doi:10.1016/j.msard.2024.105787]

  • Saposnik G, Monreal E, Medrano N, García-Domínguez JM, Querol L, Meca-Lallana JE, Landete L, Salas E, Meca-Lallana V, García-Arcelay E, Agüera-Morales E, Martínez-Yélamos S, Gómez-Ballesteros R, Maurino J, Villar LM, Caminero AB.

    Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 90: 105838-105838.

    [doi:10.1016/j.msard.2024.105838]